Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 1:04 AM ET

Healthcare Providers and Services

Company Overview of The Vanderbilt-Ingram Cancer Center

Company Overview

The Vanderbilt-Ingram Cancer Center engages in cancer research, treatment, support, prevention, education, and outreach. Its cancer clinics and programs include cancer information programs, cancer supportive care clinics, and patient resource centers, as well as medical, radiation, and surgical oncology centers; and bone and soft tissue, brain tumor, endocrine surgery, gastroenterology, general clinical research, hematology, otolaryngology, outpatient transplant, patient and family support, plastic surgery, thoracic surgery, and urology clinics and programs. The company also owns specific cancer units, including gastrointestinal, gynecologic, head and neck, orthopaedic, rehabilitation thorac...

691 Preston Building

Nashville, TN 37232

United States

Founded in 1993

Phone:

615-936-5847

Fax:

615-936-1790

Key Executives for The Vanderbilt-Ingram Cancer Center

Chief Executive Officer
Chief Medical officer
Compensation as of Fiscal Year 2015.

The Vanderbilt-Ingram Cancer Center Key Developments

Incyte Corporation and Vanderbilt-Ingram Cancer Center Establish Multi-Year Oncology Research Alliance

Incyte Corporation announced that it has entered into a multi-year research support and collaboration agreement with Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC), whereby Incyte will provide funding for certain aspects of Vanderbilt’s cancer research activities. This alliance is designed to develop an improved understanding of basic cancer biology and the mechanisms of action of certain Incyte-proprietary compounds, as well as identify and develop novel approaches to patient selection which may enable new therapeutic opportunities in oncology.

Insight Genetics, Inc. and Vanderbilt-Ingram Cancer Center Partner to Improve Breast Cancer Diagnosis and Treatment

Insight Genetics, Inc. announced that it is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to enhance how researchers and oncologists classify and treat patients diagnosed with triple-negative breast cancer (TNBC) and to identify genetic markers that will help select the targeted therapeutics most effective for each individual TNBC patient. The American Cancer Society estimates that more than 230,000 women will be diagnosed with an invasive form of breast cancer in 2014. Breast tumors that do not express genes for any of these three known markers are classified as triple-negative breast cancers. Patients with TNBC currently have limited treatment options and a higher risk of relapse than other forms of the disease. As part of their research project, Insight Genetics will be collaborating with Jennifer Pietenpol, Ph.D., director of VICC, and B.F. Byrd Jr., Professor of Oncology, as well as the laboratory group at VICC in a continuation of their work to identify novel genetic markers for TNBC. Recent work from the Pietenpol laboratory published in the Journal of Clinical Investigation used an algorithm to examine gene expression data from more than 500 TNBC cases and identified up to six distinct sub-types of triple-negative breast cancers. Insight Genetics and Dr. Pietenpol will now focus on identifying novel genetic drivers for these various TNBC sub-types and developing a better understanding of effective treatment options for each. The work is also designed to identify new TNBC biomarkers and develop assays based on these biomarkers.

Vanderbilt-Ingram Cancer Center and GenomOncology Announces an Agreement for the Exclusive Commercial Development of Decision Support Tool Based on My Cancer Genome

Vanderbilt-Ingram Cancer Center and GenomOncology have announced an agreement for the exclusive commercial development of a decision support tool based on My Cancer Genome, an online precision cancer medicine knowledge resource for physicians, patients, caregivers and researchers. The agreement should improve the way oncologists deliver genome-directed care across the country. Through this collaboration, GenomOncology, based in Westlake, Ohio, and VICC will enhance My Cancer Genome through the development of a new genomics content management tool. The MyCancerGenome.org website will remain free and open to the public. In addition, GenomOncology will develop a decision support tool based on My Cancer Genome data that will enable automated interpretation of mutations in the genome of a patient's tumor, providing actionable results in hours versus days. According to the terms of the agreement, all commercial use of My Cancer Genome in any form will be licensed through GenomOncology.

Similar Private Companies By Industry

Company Name Region
Palladium for Surgery - Dallas Ltd. United States
Southern Health Corporation of Houston, Inc. United States
Catalyst Rx Health Initiatives, Inc. United States
Boca Anesthesia Service, Inc. United States
Mass Behavioral Health Partnership United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Vanderbilt-Ingram Cancer Center, please visit www.vicc.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.